
A close-up of hands holding a tablet and a pen

Description automatically generated**U.S. Multiple Myeloma Therapeutics Market**

According to Intelli, the U.S. Multiple Myeloma Therapeutics Market size was valued at USD 14,976.2 Million in 2024 and is projected to reach USD 23,307.20 Million by 2032, growing at a CAGR of 6.21% from 2025 to 2032.



Multiple Myeloma (MM) is a complex and aggressive hematologic malignancy characterized by the uncontrolled proliferation of abnormal plasma cells in the bone marrow. These malignant cells interfere with the production of normal blood cells, disrupt bone homeostasis, and secrete a monoclonal protein (M protein) that can cause organ damage, particularly to the kidneys. MM is the second most common blood cancer after non-Hodgkin lymphoma and accounts for approximately 1–2% of all cancers globally. The pathogenesis of multiple myeloma is multifactorial, involving genetic mutations, alterations in the bone marrow microenvironment, immune evasion, and chronic inflammation. Clinically, patients may present with bone pain, fatigue, anemia, hypercalcemia, renal dysfunction, and frequent infections. Diagnosis typically relies on a combination of blood tests (including serum protein electrophoresis), bone marrow biopsy, imaging studies, and assessment of organ involvement, summarized by the CRAB criteria (Calcium elevation, Renal impairment, Anemia, Bone lesions). Treatment for multiple myeloma is typically structured in distinct phases, induction, consolidation, and maintenance, with each stage personalized according to the patient’s age, overall health, genetic risk factors, and stage of the disease. Although multiple myeloma is still considered incurable in most cases, the advent of novel therapeutic options has markedly prolonged survival and enhanced patients’ quality of life.

**U.S. Multiple Myeloma Therapeutics Market Definition**

​The U.S. Multiple Myeloma Therapeutics Market encompasses the spectrum of medical treatments and interventions aimed at managing and treating multiple myeloma. This market includes a range of therapeutic modalities such as chemotherapy, immunomodulatory agents, proteasome inhibitors, monoclonal antibodies, stem cell transplantation, and emerging treatments like CAR T-cell therapy.

**U.S. Multiple Myeloma Therapeutics Market Overview**

A close-up of hands holding a tablet and a pen

Description automatically generatedThe U.S. Multiple Myeloma Therapeutics Market is primarily driven by several key factors that are shaping its steady growth trajectory. A major driver is the rising prevalence of multiple myeloma, particularly among the aging population, as the disease is more common in individuals over 60. In addition, the therapeutic landscape for multiple myeloma is rapidly evolving due to ongoing innovations in treatment modalities. Established therapies such as proteasome inhibitors (e.g., bortezomib, carfilzomib) and immunomodulatory drugs (e.g., lenalidomide, pomalidomide) continue to play a central role in first-line and relapsed settings. Meanwhile, monoclonal antibodies like daratumumab and elotuzumab have added a new dimension to targeted therapy by enhancing immune-mediated destruction of myeloma cells. Beyond these, next-generation therapies, including CAR T-cell therapies, which re-engineer a patient’s immune cells to attack cancer, and bispecific antibodies, which bind to both myeloma cells and immune effector cells, are offering new hope for patients with relapsed or refractory disease. These advancements are not only extending survival but are also enhancing the quality of life, thereby driving strong demand for innovative therapeutics and expanding the market potential significantly. The market also benefits from a robust and well-funded healthcare infrastructure, which facilitates early diagnosis, access to advanced therapies, and improved patient monitoring. Moreover, increased investment in oncology research and development by pharmaceutical and biotech companies is leading to the approval of more targeted and effective treatments. Together, these factors contribute to a dynamic and evolving therapeutic landscape in the U.S. multiple myeloma market.

**U.S. Multiple Myeloma Therapeutics Market Segmentation**

The U.S. Multiple Myeloma Therapeutics Market is segmented based on treatment type, route of administration, distribution channel, and end-user, allowing for targeted analysis of therapy utilization and market dynamics across the healthcare ecosystem.

**U.S. Multiple Myeloma Therapeutics Market, By Treatment Type**

* **Chemotherapy**
* **Targeted Therapy**
* **Monoclonal Antibodies**
* A close-up of hands holding a tablet and a pen

  Description automatically generated**Immunotherapy**
* **Stem Cell Transplantation**
* **Radiation Therapy**

The chemotherapy segment, encompassing conventional cytotoxic agents, held the second-largest share, though its proportion is gradually decreasing as newer therapies gain prominence. Stem cell transplantation, particularly autologous stem cell transplantation, remains a cornerstone for eligible patients. Radiation therapy and immunotherapy, including CAR T-cell therapies like CARVYKTI and bispecific antibodies such as Elranatamab, represent rapidly emerging segments in the treatment of multiple myeloma. Immunotherapies, in particular, are experiencing significant growth, driven by their ability to deliver durable responses, especially in patients with relapsed or refractory disease.

**U.S. Multiple Myeloma Therapeutics Market, By Route of Administration**

* **Oral**
* **Injectable**

The U.S. Multiple Myeloma Therapeutics Market, by route of administration, is primarily divided into oral and injectable segments. Oral therapies, such as lenalidomide and thalidomide, are increasingly popular due to their convenience, allowing patients to manage treatment at home and reducing the need for frequent hospital visits. On the other hand, injectable therapies including monoclonal antibodies, proteasome inhibitors, and emerging immunotherapies like CAR T-cell therapies remain essential for active treatment phases, particularly in aggressive or advanced stages of multiple myeloma. The injectable segment continues to dominate, especially in first-line and combination therapies, offering potent and targeted mechanisms of action.

**U.S. Multiple Myeloma Therapeutics Market,** **By Distribution Channel**

* **Hospital Pharmacies**
* **Retail Pharmacies**
* **Specialty Pharmacies**

A close-up of hands holding a tablet and a pen

Description automatically generatedThe U.S. Multiple Myeloma Therapeutics Market, by distribution channel, is segmented into hospital pharmacies, retail pharmacies, and specialty pharmacies. Hospital pharmacies play a pivotal role in the market, particularly in the administration of complex therapies. Retail pharmacies serve as a key distribution point for oral therapies. Meanwhile, specialty pharmacies are specifically focused on high-cost, complex, or biologic treatments, such as targeted therapies and immunotherapies. These pharmacies ensure proper patient adherence, provide counseling, and help manage insurance-related issues, making them crucial for patients on long-term or specialized regimens.

**U.S. Multiple Myeloma Therapeutics Market, By End-User**

* **Hospitals**
* **Specialty Clinics**
* **Homecare Settings**

The U.S. Multiple Myeloma Therapeutics Market, by end-user, is divided into hospitals, specialty clinics, and homecare settings. Hospitals remain the dominant end-user, particularly for patients undergoing intensive treatments. Specialty clinics cater to outpatient care and are central to the ongoing management of multiple myeloma, offering targeted therapies, immunotherapy infusions, and regular monitoring, typically for patients in remission or receiving maintenance treatment. With advancements in treatment options, homecare settings are also seeing significant growth, as patients can now receive oral therapies and supportive care at home. Additionally, homecare services may include at-home infusion of certain injectable treatments, offering greater convenience and improving quality of life for patients.

**Key Players**

The “U.S. Multiple Myeloma Therapeutics Market" study report will provide valuable insight emphasizing the U.S. market. The major players in the market Johnson & Johnson, Amgen Inc., Bristol-Myers Squibb, AbbVie Inc., Merck & Co. Inc., Novartis AG, Sanofi S.A., GSK, Regeneron Pharmaceuticals, Eli Lilly and Co., Roche Holding AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd. among others. Our market analysis also entails a section solely dedicated to such major players wherein A close-up of hands holding a tablet and a pen

Description automatically generatedour analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

**Key Developments**

* In 2024, Bristol Myers Squibb and 2seventy bio announced a collaboration to develop new cell therapies for multiple myeloma, aiming to enhance patient outcomes.
* In 2024, GSK's Blenrep, when combined with bortezomib and dexamethasone, showed a 42% reduction in mortality risk for patients with relapsed multiple myeloma. The FDA is expected to decide on its new license application by July 2025, marking a significant innovation in the treatment landscape.

**Market Attractiveness**

The image of market attractiveness provided further helps to get information about the region leading in the U.S. Multiple Myeloma Therapeutics Market. We cover the major impacting factors driving the industry growth in the given region.

**Porter’s Five Forces**

The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape U.S. Multiple Myeloma Therapeutics Market, gauge the attractiveness of a particular sector, and assess investment possibilities.

A close-up of hands holding a tablet and a pen

Description automatically generatedTABLE OF CONTENT

1 **INTRODUCTION OF** **U.S. MULTIPLE MYELOMA THERAPEUTICS MARKET**

* 1. Overview of the market
  2. Scope of report
  3. Assumptions

1. **EXECUTIVE SUMMARY**
2. **RESEARCH METHODOLOGY**
   1. Data Mining
   2. Validation
   3. Primary Interviews
   4. List of Data sources
3. **U.S. MULTIPLE MYELOMA THERAPEUTICS MARKET OUTLOOK**
   1. Overview
   2. Market Dynamics
      1. Drivers
      2. Restrains
      3. Opportunities
      4. Trends
   3. Portes Five FORCE Model
   4. Value Chain Analysis

**5 U.S. MULTIPLE MYELOMA THERAPEUTICS MARKET, BY TREATMENT TYPE**

5.1 Overview

A close-up of hands holding a tablet and a pen

Description automatically generated5.2 Chemotherapy

5.3 Targeted Therapy

5.4 Monoclonal Antibodies

5.5 Immunotherapy

5.6 Stem Cell Transplantation

5.7 Radiation Therapy

**6 U.S. MULTIPLE MYELOMA THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION**

6.1 Overview

6.2 Oral

6.3 Injectable

**7** **U.S. MULTIPLE MYELOMA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL**

7.1 Overview

7.2 Hospital Pharmacies

7.3 Retail Pharmacies

7.4 Specialty Pharmacies

1. **U.S. MULTIPLE MYELOMA THERAPEUTICS MARKET, BY END USER**
   1. Overview
   2. Hospitals
   3. Specialty Clinics
   4. A close-up of hands holding a tablet and a pen

      Description automatically generated Homecare Settings
2. **U.S. MULTIPLE MYELOMA THERAPEUTICS MARKET COMPETITIVE LANDSCAPE**
   1. Overview
   2. Company Market Ranking
   3. Key Developments Strategies
3. **COMPANY PROFILES**

**10.1 Johnson & Johnson**

* + 1. Overview
    2. Financial Performance
    3. roduct Outlook
    4. Key developments
  1. **Amgen Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  2. **Bristol-Myers Squibb**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. **AbbVie Inc.**
     1. Overview
     2. A close-up of hands holding a tablet and a pen

        Description automatically generatedFinancial Performance
     3. Product Outlook
     4. Key developments
  4. **Merck & Co. Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. **Novartis AG**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  6. **Sanofi S.A.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  7. **GSK**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments

* 1. **Regeneron Pharmaceuticals**
     1. Overview
     2. A close-up of hands holding a tablet and a pen

        Description automatically generatedFinancial Performance
     3. Product Outlook
     4. Key developments
  2. **Eli Lilly and Co.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  3. **Roche Holding AG**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  4. **Pfizer Inc.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  5. **F. Hoffmann-La Roche Ltd.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments
  6. **Gilead Sciences Inc.**
     1. Overview
     2. Financial Performance
     3. A close-up of hands holding a tablet and a pen

        Description automatically generatedProduct Outlook
     4. Key developments
  7. **Teva Pharmaceutical Industries Ltd.**
     1. Overview
     2. Financial Performance
     3. Product Outlook
     4. Key developments

1. **KEY DEVELOPMENTS**
   1. Product Launches/Developments
   2. Merges and Acquisitions
   3. Business Expansions
   4. Partnerships and Collaborations
2. **Appendix**

12.1 Related Research